Drug Maker Staging a Comeback After Yesterday’s Debacle
Drug developer Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) watched its shares plummet 35% yesterday following a report that rheumatoid arthritis treatment it was developing with AstraZeneca plc (NYSE: AZN) did not ...Read Full Story »
